98 research outputs found
National competitiveness as the object of indicative planning in the context of re-industrialization
Three years after the adoption of legislation regarding strategical planning we are able to see the first statistical results, reflecting actual conditions of regulated objects. The subject of this article is to examine the system of indicators of state economic policy, targeting to stimulate the development of economic potential with the aim to improve national economic competitiveness. The objective is the competitiveness of domestic economy as the subject of regulation.
The aim is the analysis of the system of indicators on the basis of comparison of actual and planned data, detecting weakly correlated indicators and to make recommendations to correct the system of indicators. The article analyses the indicators that are being used in normative and legal documents. The authors consider long-term and medium-term targets for economic frontier development, as well as main factors that should be accounted while formulating the system of indicators for the economic potential in long- and medium-term.
As the list of indicators of economic development in the strategic documents is vast, the chosen direction considers the production with high added value. The indicators considered reflect the indicative aim of scientific development, national innovation system and technology as the most important foundations for improvement of national economic competitiveness. Multidirectional trend of economic development and administration indicators has been detected. The formation of system of supplementary indicators that reflect the development of production frontier has been proposed.peer-reviewe
Homobivalent Lamellarin-Like Schiff Bases: In Vitro Evaluation of Their Cancer Cell Cytotoxicity and Multitargeting Anti-Alzheimer's Disease Potential
Marine alkaloids belonging to the lamellarins family, which incorporate a 5,6-dihydro-1-phenylpyrrolo[2,1-a]isoquinoline (DHPPIQ) moiety, possess various biological activities, spanning from antiviral and antibiotic activities to cytotoxicity against tumor cells and the reversal of multidrug resistance. Expanding a series of previously reported imino adducts of DHPPIQ 2-carbaldehyde, novel aliphatic and aromatic Schiff bases were synthesized and evaluated herein for their cytotoxicity in five diverse tumor cell lines. Most of the newly synthesized compounds were found noncytotoxic in the low micromolar range (<30 ΞΌM). Based on a Multi-fingerprint Similarity Search aLgorithm (MuSSeL), mainly conceived for making protein drug target prediction, some DHPPIQ derivatives, especially bis-DHPPIQ Schiff bases linked by a phenylene bridge, were prioritized as potential hits addressing Alzheimer's disease-related target proteins, such as cholinesterases (ChEs) and monoamine oxidases (MAOs). In agreement with MuSSeL predictions, homobivalent para-phenylene DHPPIQ Schiff base 14 exhibited a noncompetitive/mixed inhibition of human acetylcholinesterase (AChE) with Ki in the low micromolar range (4.69 ΞΌM). Interestingly, besides a certain inhibition of MAO A (50% inhibition of the cell population growth (IC50) = 12 ΞΌM), the bis-DHPPIQ 14 showed a good inhibitory activity on self-induced Ξ²-amyloid (AΞ²)1-40 aggregation (IC50 = 13 ΞΌM), which resulted 3.5-fold stronger than the respective mono-DHPPIQ Schiff base 9
SCLERODERMA SYSTEMATICA WITH INTERSTITIAL LUNG LESION: COMPARATIVE CLINICAL CHARACTERISTICSWITH PATIENTS WITHOUT LUNG LESION
Objective. To compare disease history data and clinical and laboratory parameters in patients with scleroderma systematica (SDS) with high-resolution computed tomography (HRCT)-verified interstitial lung lesion (ILL) versus those without lung involvement. Subjects and methods. An examination was made in 138 patients with SDS who had been consecutively admitted in 2006-2008, female/male ratio, 124 : 14; limited : diffuse : mixed forms, 78 : 40 : 20; mean age, 47Β±13 years; median disease duration, 6 (2.5 11) years. The history data (occupational hazards, smoking, respiratory diseases) and clinical manifestations of SDS and laboratory data were studied. The diagnosis of ILL was established on the basis of chest HRCT. Results. According to HRCT data, the signs of varying ILL were found in 82% of the patients with SDS. The duration of SDS was similar in the patients with and without lung involvement; but the latter were younger at the time of disease onset. There were no significant differences between the groups compared in history data, clinical forms of SDS, the frequency of involvement of visceral organs and systems. Crepitation was heard only in the patients with ILL. The frequency of respiratory manifestations increased with a larger number of the involved lung segments. The prevalence of ILL was found to be positively correlated with age at the onset of SDS (r=0.29;
ΠΡΠΎΠ±Π»Π΅ΠΌΠ° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ
The problem of systemic scleroderma (SSD) activity enters into the view of standardized patient examination and it is important for choosing a therapeutic complex, for determining the dose of drugs, and for monitoring therapy. Great difficulties in the determination of activity in SSD are caused by the pathogenetic and morphogenetic features of the disease. It should be emphasized that there are no clearly defined exacerbation and remission periods. It is difficult to differentiate the potentially reversible inflammatory changes determining the activity of SSD from the irreversible fibrous changes characterizing the severity of the disease. The laboratory parameters of inflammatory activity are also of little informative value. The complicated problem of activity in SSD is to be further investigated both to improve and modify existing indices and to search for a common specific marker and/or key pathogenetically and clinically relevant markers of disease activity.ΠΡΠΎΠ±Π»Π΅ΠΌΠ° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ (Π‘Π‘Π) Π½Π΅ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ²ΡΠ·Π°Π½Π° ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΠ΅ΠΉ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈ Π²Π°ΠΆΠ½Π° Π΄Π»Ρ Π²ΡΠ±ΠΎΡΠ° Π»Π΅ΡΠ΅Π±Π½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ°, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π΄ΠΎΠ·Ρ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠΎΠ»ΡΡΠΈΠ΅ ΡΡΡΠ΄Π½ΠΎΡΡΠΈ Π² ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈ Π‘Π‘Π ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΠΌΠΈ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° ΠΈ ΠΌΠΎΡΡΠΎΠ³Π΅Π½Π΅Π·Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π‘Π»Π΅Π΄ΡΠ΅Ρ ΠΏΠΎΠ΄ΡΠ΅ΡΠΊΠ½ΡΡΡ, ΡΡΠΎ ΠΏΡΠΈ Π‘Π‘Π Π½Π΅Ρ ΡΠ΅ΡΠΊΠΎ ΠΎΡΠ΅ΡΡΠ΅Π½Π½ΡΡ
ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΎΠ² ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΡ ΠΈ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ. Π Π°Π·Π³ΡΠ°Π½ΠΈΡΠΈΡΡ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΠΎΠ±ΡΠ°ΡΠΈΠΌΡΠ΅ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ, ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΠΈΠ΅ Β«Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΒ» Π‘Π‘Π, ΠΎΡ Π½Π΅ΠΎΠ±ΡΠ°ΡΠΈΠΌΡΡ
ΡΠΈΠ±ΡΠΎΠ·Π½ΡΡ
, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΡ
ΡΡΠΆΠ΅ΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΡΠ»ΠΎΠΆΠ½ΠΎ. ΠΠ°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ°ΠΊΠΆΠ΅ ΠΌΠ°Π»ΠΎ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½Ρ. ΠΠ΅ΠΏΡΠΎΡΡΠ°Ρ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈ Π‘Π‘Π ΠΏΠΎΠ΄Π»Π΅ΠΆΠΈΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΌΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΊΠ°ΠΊ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΈΠΌΠ΅ΡΡΠΈΡ
ΡΡ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ², ΡΠ°ΠΊ ΠΈ ΠΏΠΎΠΈΡΠΊΠ° Π΅Π΄ΠΈΠ½ΠΎΠ³ΠΎ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ/ΠΈΠ»ΠΈ Β«ΠΊΠ»ΡΡΠ΅Π²ΡΡ
Β» ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ
STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA
Interstitial lung disease (ILD) is one of the major causes of death in systemic scleroderma (SSD). Treatment of these patients remains difficult and controversial. Mycophenolate mofetil (MPM) has been in vitro shown to inhibit overproduction of type I collagen and hence may be effective against SSD. Objective: to study the efficiency and safety of MPM therapy in patients with SSD and clinically relevant ILD in an open-label prospective study. Subjects and methods. Ten patients with SSD (7 and 3 with its diffuse and limited forms, respectively) and ILD were given MPM in combination with glucocorticoids (mean daily dose was 10+4 mg). The mean MPM therapy duration was 11.4+1.3 months. The Rodnan total skin thickness score, flexion index, forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), and European Scleroderma Study Group (EScSG) activity index were estimated and a 6-minute walk test (6MWT) was carried out before and after MPM therapy. Results. After therapy, the whole group showed a significant reduction in skin scores from 12.9+9.8 to 5.6+3.2 (p=0.036) and EScSG from 3.9+1.4 to 2.25+1.03 (p=0.015) and an increase in exercise tolerance from 446+155 to 535+78 m (p=0.03) as evidenced by 6MWT. The degree of flexion contractures decreased from 15+21 to 3.7+11.3 mm (p>0.05). FVC (77.8+18.7% versus 73.8+11.3%) and DLCO (45+14.4% versus 42+16.4%) were significantly unchanged. A 10% or more clinically significant fall was noted in FVC and DLCO in 3 and 1 patients, respectively. In the remaining patients, the lung functional test results remained stable. MPM tolerability was satisfactory. All the patients completed their course of treatment. Conclusion. Stabilization of lung function with higher exercise tolerance and significantly reduced skin density allow therapy with MPM in combination with low-dose glucocorticoids to be regarded as an effective and well-tolerated treatment in patients with ILD in the presence of SS
Cytokine profile and expression of FYN, ZAP-70 and LAT during concanavalin a stimulation in patients with resistant bronchial asthma
Background: Bronchial asthma (BA) is one of the most spreading chronic lung pathology in the world. The disease is characterized by high heterogeneity of clinical phenotypes including resistant forms which provoke significant clinical problem. Immune shift from Th2 to alternative immunological response is considered to be a mechanism of drug-resistance in BA treatment but this issue is not considerably studied yet. Aims: Detection of distinctive patterns in cytokine secretion and genetic expression (ZAP-70, FYN and LAT) of naΓ―ve and concanavalin A stimulated lymphocytes in patients with resistant BA. Materials and methods: The study enrolled ten patients in each group: subjects with treatment resistant BA, severe BA, and controls (30 in total). During the experiment, all patients with BA received treatment according to the condition. For each participant lymphocytes isolation from venous blood was performed. Cells were cultured with concanavalin A and without stimulation. Concentrations of cytokines IL-2, IL-12, TNF-Ξ±, IL-4, IL-5, and IL-6 in supernatants were measured with ELISA. Reverse transcription polymerase chain reaction was used to detect the mRNA expression of LAT, ZAP-70, and FYN genes. Results: Significant disease contribution to the lymphocyte secretion profile was established without concanavalin A stimulation: increased levels of IL-2 and IL-4 was observed in lymphocytes of patients with resistant BA if compared to the results of gorup with severe BA. Patients with resistant BA were characterized by weak cytokine response to the stimulation: only TNF-Ξ± and IL-5 levels were significantly increased whereas in group with severe BA all cytokines concentrations increased except IL-12, in controls - except IL-12 and IL-2. Significant FYN upregulation was identified in resistant BA group if compared with other groups, and in severe BA patients if compared with controls. The concanavalin A-stimulated cells showed increased expression of ZAP-70 in cells of patients with resistant BA compared to control group. Conclusions: Lymphocytes from patients with resistant BA are characterized by lack of cytokine response to concanavalin A stimulation, alteration of cytokine secretion, and genetic expression profile similar to cells with low sensitivity to apoptosis. The FYN gene is a perspective target for finding approaches to overcome resistance to steroid drugs in bronchial asthma. Β© 2018 Izdatel'stvo Meditsina. All rights reserved
The ves hypothesis and protein misfolding
Proteins function by changing conformation. These conformational changes, which involve the concerted motion of a large number of atoms are classical events but, in many cases, the triggers are quantum mechani-
cal events such as chemical reactions. Here the initial quantum states after
the chemical reaction are assumed to be vibrational excited states, something
that has been designated as the VES hypothesis. While the dynamics under
classical force fields fail to explain the relatively lower structural stability of
the proteins associated with misfolding diseases, the application of the VES hy-
pothesis to two cases can provide a new explanation for this phenomenon. This explanation relies on the transfer of vibrational energy from water molecules to proteins, a process whose viability is also examined
ΠΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΡ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠ°ΠΌΠΌΠΎΡΡΠ΅ΡΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ il-6 ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΡΠ²ΠΎΠ»ΠΎΠ²ΠΎΠΉ ΠΏΠ»Π°ΡΡΠΈΡΠ½ΠΎΡΡΠΈ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
The aim of the study was mammosphere assay optimization for quantifcation of IL6-induced stemness in differentiated (Π‘D44β ) T47D breast cancer cells.Material and Methods. The effect of three commonly used cell-detaching methods (TrypLE, accutase, cell scrapper) at various confuence (40β50 % and 70β80 %) on cell viability, phenotypic profle and mammosphere formation was tested. The cell viability was examined using AnnexinV/propidium iodide assay. The phenotypic profle was analyzed by fow cytometry with fuorescent markers CD24 and CD44.Results. Detachment of the cells using scrapper led to substantial increase in early apoptotic and late apoptotic cells in comparison with TrypLE and accutase. Dissociation with TrypLE reduced the percentage of detected CD44+ positive cells, whereas accutase saved the surface marker. The number of mammosphere and their diameter did not differ between groups. Incubation of differentiated (CD44β CD24+) T47D cells with IL-6 for 24 hours resulted in an appearance of CD44+CD24+ and CD44+CD24β/low subpopulation. Furthermore, the differentiated cells after 24 hours of IL6 exposure formed 3 times more mammospheres compared to the control.Conclusion. Usage of cells with confuence of no more than 80 % and accutase for detachment of cells is recommended for mammosphere assay. Incubation of CD44β CD24+ T47D cells with IL6 for 24 hours is suffcient for stimulation of stemness plasticity.Β Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΡ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΎΡΠ΅Π½ΠΊΠΈ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠ°ΠΌΠΌΠΎΡΡΠ΅Ρ ΠΏΠΎΡΠ»Π΅ ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½ΠΎΠΌ 6 (IL6) ΡΡΠ²ΠΎΠ»ΠΎΠ²ΠΎΠΉ ΠΏΠ»Π°ΡΡΠΈΡΠ½ΠΎΡΡΠΈ Ρ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
(CD44β ) ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ Π»ΠΈΠ½ΠΈΠΈ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° T47D.ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° ΠΆΠΈΠ·Π½Π΅ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ, ΡΠΈΡΠΎΡΠ»ΡΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΠΈΡ
ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΠΊ ΠΌΠ°ΠΌΠΌΠΎΡΡΠ΅ΡΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠΉ ΠΈΡΡ
ΠΎΠ΄Π½ΠΎΠΉ ΠΊΠΎΠ½ΡΠ»ΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ (40β50 % ΠΈ 70β80 %) ΠΈ ΠΌΠ΅ΡΠΎΠ΄Π°Ρ
ΡΠ½ΡΡΠΈΡ Ρ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ ΠΏΠ»Π°ΡΡΠΈΠΊΠ° (ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ TrypLE, Π°ΠΊΠΊΡΡΠ°Π·Ρ, ΡΠΊΡΠ΅Π±ΠΊΠ° Π΄Π»Ρ ΠΊΠ»Π΅ΡΠΎΠΊ). ΠΠΈΠ·Π½Π΅ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΉ ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠ½ΠΎ-ΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΠ½Π½Π΅ΠΊΡΠΈΠ½V ΠΈ ΠΉΠΎΠ΄ΠΈΡΡΠΎΠ³ΠΎ ΠΏΡΠΎΠΏΠΈΠ΄ΠΈΡ. ΠΠΈΠ½Π°ΠΌΠΈΠΊΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠ½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΉ ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΠΈ Ρ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠ½ΠΎ-ΠΌΠ΅ΡΠ΅Π½Π½ΡΠΌΠΈ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌΠΈ ΠΊ CD24 ΠΈ CD44.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠΊΡΠ΅Π±ΠΊΠ° Π΄Π»Ρ ΡΠ½ΡΡΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΠ»ΠΎ ΠΊ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΌΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΠΊΠ»Π΅ΡΠΎΠΊ Ρ ΡΠΈΡΠΎΡΠ»ΡΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ ΡΠ°Π½Π½Π΅Π³ΠΎ ΠΈ ΠΏΠΎΠ·Π΄Π½Π΅Π³ΠΎ Π°ΠΏΠΎΠΏΡΠΎΠ·Π° ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ TrypLE ΠΈ Π°ΠΊΠΊΡΡΠ°Π·Ρ. ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ TrypLE ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΠ»ΠΎ ΠΊ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° CD44+ ΠΊΠ»Π΅ΡΠΎΠΊ, ΡΠΎΠ³Π΄Π° ΠΊΠ°ΠΊ Π°ΠΊΠΊΡΡΠ°Π·Π° Π½Π΅ Π²Π»ΠΈΡΠ»Π° Π½Π° ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΡΡΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ°. ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΌΠ°ΠΌΠΌΠΎΡΡΠ΅Ρ ΠΈ ΠΈΡ
ΡΡΠ΅Π΄Π½ΠΈΠΉ Π΄ΠΈΠ°ΠΌΠ΅ΡΡ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°Π»ΠΈΡΡ ΠΌΠ΅ΠΆΠ΄Ρ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΠΌΠΈ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ. Π‘ΡΠΈΠΌΡΠ»ΡΡΠΈΡ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
(CD44β CD24+) ΠΊΠ»Π΅ΡΠΎΠΊ Π»ΠΈΠ½ΠΈΠΈ T47D IL6 ΡΠΆΠ΅ ΡΠ΅ΡΠ΅Π· 24 Ρ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΠ»Π° ΠΊ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ CD44+CD24+ ΠΏΡΠΎΠ³Π΅Π½ΠΈΡΠΎΡΠ½ΡΡ
ΠΈ CD44+CD24β/low ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΡΡΠ²ΠΎΠ»ΠΎΠ²ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ. ΠΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΊΠ»Π΅ΡΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ IL6 Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 24 Ρ ΠΎΠ±ΡΠ°Π·ΠΎΠ²ΡΠ²Π°Π»ΠΈ Π² 3 ΡΠ°Π·Π° Π±ΠΎΠ»ΡΡΠ΅ ΠΌΠ°ΠΌΠΌΠΎΡΡΠ΅Ρ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΌΠ°ΠΌΠΌΠΎΡΡΠ΅ΡΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ ΠΊΠ»Π΅ΡΠΊΠΈ Ρ ΠΊΠΎΠ½ΡΠ»ΡΠ΅Π½ΡΠ½ΠΎΡΡΡΡ Π΄ΠΎ 80 % ΠΈ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡ Π°ΠΊΠΊΡΡΠ°Π·Ρ Π΄Π»Ρ ΡΠ½ΡΡΠΈΡ Ρ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ ΠΏΠ»Π°ΡΡΠΈΠΊΠ°. ΠΠ»Ρ ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ ΡΡΠ²ΠΎΠ»ΠΎΠ²ΠΎΠΉ ΠΏΠ»Π°ΡΡΠΈΡΠ½ΠΎΡΡΠΈ Ρ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ Π»ΠΈΠ½ΠΈΠΈ T47D Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΈΡ
ΠΈΠ½ΠΊΡΠ±Π°ΡΠΈΡ Ρ IL6 Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 24 Ρ.
- β¦